bpc 157 retatrutide BPC-157 Europe - RUO Research Peptide BPC-157 / TB-500 Mix |
Description
presence of gastrointestinal symptoms
Ultimately, whether microdosing becomes mainstream will depend on future clinical evidence
Your health journey is personal, and only you can determine the right approach
The practical implication is that poor early response is uncommon and doesnt necessarily predict poor ultimate outcomes
Participants lost roughly 19% to 20% of their body weight on average over more than a year of treatment, compared to a roughly 16% average for those on the lower dose
